Archive for the ‘Vioxx News and Information’ Category
More than £2 billion has been paid out to 44,000 Americans who took victims of the painkiller, called Vioxx, which was taken off the market in 2004. But the makers of the drug, Merck, have not paid anything in this country. Merck stressed that it … Originally Syndicated via RSS from vioxx - Live Search News
NEW YORK (Reuters) - The glory is quickly fading for drugmaker Merck & Co, which dazzled investors over the past three years by recovering from a crisis over its Vioxx painkiller and rolling out blockbuster products. For now the stock is looking more … Originally Syndicated via RSS from vioxx - Live Search News
In the latest disappointment for the cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn’t prevent worsening of the disease or lower the need for valve surgery. Results of a preliminary analysis … Originally Syndicated via RSS from vioxx - Live Search News
January February March April May June July August September October November December 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 Foreign tourists aren’t the only ones who see the United States as a great value right now … Originally Syndicated via RSS from vioxx - Live Search News
Merck , the US pharmaceuticals group, played down the risks of taking its painkiller Vioxx in reports in academic journals and early submissions to regulators, according to a study to be published on Wednesday. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Merck & Co.’s (MRK) report of improved second-quarter earnings was overshadowed Monday by a new study raising questions about its cholesterol drugs, while the quarterly numbers confirmed fears of a slowdown in sales of cervical-cancer vaccine … Originally Syndicated via RSS from vioxx - Live Search News
NEW YORK (Dow Jones) — Merck (MRK) posted a 5% increase in second-quarter net income, as the company pulled its 2008 and long-term guidance because of study results released earlier Monday that show Vytorin failed to show a benefit in people with a … Originally Syndicated via RSS from vioxx - Live Search News
Merck & Co. (MRK) posted a 5% increase in second-quarter net income, as the company pulled its 2008 and long-term guidance because of study results released earlier Monday that show Vytorin failed to show a benefit in people with a heart-valve … Originally Syndicated via RSS from vioxx - Live Search News
Merck & Co., Inc. today announced financial results for the second quarter of 2008. Merck reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) of $0.86 for the second quarter of 2008, excluding restructuring charges … Originally Syndicated via RSS from vioxx - Live Search News
As the son of a doctor and the husband of another, I’m always on the lookout for irresponsible health journalism. And, boy, did I find some this weekend. Yesterday’s New York Post featured an “EXCLUSIVE” headlined “My girl died as ‘guinea pig’ for … Originally Syndicated via RSS from vioxx - Live Search News |
|